A licensing pact with Pfizer Inc. is a key vote of confidence for Phytopharm PLC, a fledgling British firm that is combing jungles from South Africa to Indonesia in search of new plant-based medicines. Under an agreement potentially worth up to $32 millions in research funding, license fees and other payments, Phytopharm granted Pfizer exclusive rights to an experimental drug against obesity.